Extrachromosomal DNA (ecDNA) is linked to aggressive glioma behavior and poor outcomes, influencing chromatin structures (ref: Taghbalout doi.org/10.1016/j.ccell.2025.08.008/).
IDH-mutant astrocytomas exhibit immune-hot subtypes associated with worse prognosis, validated across multiple cohorts (ref: Tang doi.org/10.1016/j.ccell.2025.08.006/).
Targeting mitochondrial stress in glioblastoma can enhance innate immunity and reduce tumor recurrence (ref: Han doi.org/10.1002/adma.202511351/).
Proton craniospinal irradiation significantly improves CNS progression-free survival compared to conventional therapies (ref: Yang doi.org/10.1001/jamaoncol.2025.3007/).
Hydrogen sulfide therapy reduces tumor-associated macrophage recruitment and improves survival in glioblastoma models (ref: Camarano doi.org/10.1016/j.redox.2025.103866/).
Allogeneic CAR-NKT cells targeting EGFRvIII show promise in overcoming immunosuppressive TME in glioblastoma (ref: Li doi.org/10.1016/j.ymthe.2025.09.026/).
The CBTRUS report indicates brain tumors are the most common cancer in children, necessitating continued research (ref: Price doi.org/10.1093/neuonc/).
BS1801 treatment relieves temozolomide resistance in glioma by inducing endoplasmic reticulum stress (ref: Chang doi.org/10.1016/j.redox.2025.103827/).